Neoadjuvant nivolumab plus chemotherapy significantly improved EFS in stage IB to stage IIIA resectable non-small cell lung cancer, according to research presented at American Association for Cancer Research Annual Meeting. Results of the randomized phase 3 CheckMate 816 trial, published simultaneously in The New England Journal of Medicine, also showed no new adverse events associated with the
Johns Hopkins University: Novel AI Blood Testing Technology Can ID Lung Cancers with High Accuracy indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.
Novel AI blood testing technology can identify lung cancers with high accuracy aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.
Researchers develop novel AI blood testing technology to identify lung cancers aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.
email article
Adding the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy dramatically increased pathologic complete response (pCR) in patients with operable lung cancer, a randomized trial showed.
The pCR rate increased from 2.2% with chemotherapy alone to 24.0% with the addition of nivolumab. The between-group difference increased in an analysis limited to patients who had complete resection. Clearance of circulating tumor (ct) DNA during neoadjuvant therapy increased the likelihood of pCR, reported Patrick M. Forde, MD, of the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, at the American Association for Cancer Research (AACR) virtual meeting. CheckMate 816 showed a statistically significant improvement in pCR, said Forde. This benefit was consistent across disease stages, histology, TMB (tumor mutational burden) and PD-L1 expression. The study continues to mature for the event-free survival (EFS) primary endpoint.